Research Topics
Species | K A BlumSummaryAffiliation: The Ohio State University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Upcoming diagnostic and therapeutic developments in classical Hodgkin's lymphomaKristie A Blum
Division of Hematology, The Arthur G James Comprehensive Cancer Center and The Ohio State University, Columbus, OH 43210, USA
Hematology Am Soc Hematol Educ Program 2010:93-100. 2010..This review examines current data using the IPS to determine patient outcome, discuss several potential biologic prognostic markers, and summarize new therapies that are currently in clinical development in HL...- Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridolK A Blum
Division of Hematology, Department of Internal Medicine, The Arthur G James Comprehensive Cancer Center and The Ohio State University, Columbus, OH 43210, USA
Leukemia 25:1444-51. 2011..TLS does not appear to be predictive of response or improved PFS in patients receiving flavopiridol... - Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylationKristie A Blum
Division of Hematology Oncology, Department of Internal Medicine, The Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
Br J Haematol 150:189-95. 2010..In conclusion, dose-limiting myelosuppression and infectious complications prevented dose escalation of decitabine to levels associated with changes in global methylation or gene re-expression in CLL and NHL... - Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an Fc?RIIIa-158 V/F polymorphismK A Blum
Division of Hematology Oncology, The Ohio State University Medical Center, Columbus, OH, USA
Ann Oncol 21:2246-54. 2010.... - Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemiaKristie A Blum
Division of Hematology Oncology, Ohio State University Medical Center, Columbus, OH 43210, USA
Br J Haematol 147:507-14. 2009..Future investigations in CLL should focus on broad HDAC inhibition, combination strategies, and approaches to diminish constitutional symptoms associated with this class of drugs... - Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphomaKristie A Blum
Division of Hematology Oncology, Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
Leuk Lymphoma 50:349-56. 2009..Clofarabine exhibits evidence of single agent activity in relapsed or refractory DLBCL. However, further study with novel administration schedules that maintain this efficacy and limit toxicity is warranted... - Computed tomography scans do not improve the predictive power of 1996 national cancer institute sponsored working group chronic lymphocytic leukemia response criteriaKristie A Blum
The Ohio State University, Division of Hematology Oncology, Starling Loving Hall, Room B324, Columbus, OH 43210, USA
J Clin Oncol 25:5624-9. 2007..The widespread use of computed tomography (CT) scans has prompted many to advocate for the incorporation of this test into CLL response criteria... - Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: cancer and leukemia Group B protocol 50206Kristie A Blum
Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA
Leuk Lymphoma 48:1313-9. 2007..Grade 3 - 4 adverse events, primarily thrombocytopenia, occurred in 15 patients. Therefore, although well tolerated, 1.3 mg/m(2) bortezomib administered biweekly has no single agent activity in relapsed/refractory classical HL... - Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma: results of Cancer and Leukemia Group B Study 9153Kristie A Blum
Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio 43210, USA
Cancer 107:2817-25. 2006..The objective of this study was to determine the efficacy and toxicity of 2-chlorodeoxyadenosine (2-CdA) in patients with untreated, indolent non-Hodgkin lymphoma (NHL)... - Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disordersThomas S Lin
Division of Hematology and Oncology, The Ohio State University, Center for Biostatistics, The Ohio State University, Columbus, OH 43210, USA
J Clin Oncol 28:418-23. 2010..We conducted a phase I study of flavopiridol, fludarabine, and rituximab (FFR) in patients with mantle-cell lymphoma (MCL), indolent B-cell non-Hodgkin's lymphomas (B-NHL), and CLL to determine the activity of FFR... - Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk diseaseThomas S Lin
Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA
J Clin Oncol 27:6012-8. 2009..Given the relevance of these findings to treating genetically high-risk CLL, a prospective confirmatory study was initiated... - Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphomaLapo Alinari
Department of Internal Medicine, Division of Hematology and Oncology, Ohio State University, Columbus, Ohio 43210, USA
MAbs 1:31-40. 2009.... - Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemiaMitch A Phelps
Comprehensive Cancer Center, College of Pharmacy, Division of Pharmaceutics, The Ohio State University, Columbus, OH 43210, USA
Blood 113:2637-45. 2009..These composite results confirm high activity of this pharmacokinetically derived schedule in relapsed, genetically high-risk CLL. Furthermore, PK describes some, but not all, variability in response and toxicity... - Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaJohn C Byrd
Division of Hematology Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
Blood 109:399-404. 2007..Patients with bulky disease and high-risk genetic features have achieved durable responses, thereby justifying further study of flavopiridol in CLL and other diseases... - Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomasMehdi Hamadani
Hematology and Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
Biol Blood Marrow Transplant 15:547-53. 2009..Given the outcomes seen here in the setting of PD, such patients should proceed with transplant only in the setting of investigational therapy... - High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphomaMehdi Hamadani
Department of Internal Medicine, Division of Hematology Oncology, Arthur G James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
Eur J Haematol 81:425-31. 2008..At a median follow-up of 38 months, 3-yr progression-free survival following autologous HSCT was 40%. The 3-yr overall survival was 52%. The cumulative incidence of relapse and non-relapse mortality rate was 41% and 25%, respectively... - 90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphomaKristie A Blum
The Ohio State University, Division of Hematology and Oncology, Arthur G James Cancer Hospital, Columbus 43210 1240, USA
Expert Opin Biol Ther 4:1323-31. 2004..Toxicities are primarily neutropenia and thrombocytopenia, with few infectious complications. 90Yttrium-ibritumomab tiuxetan is an effective therapeutic alternative for the treatment of NHL... - Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphomaMehdi Hamadani
Department of Hematology and Oncology and Bone Marrow Transplantation, The Ohio State University, Columbus, Ohio 43210, USA
Leuk Lymphoma 49:1893-8. 2008..Day 100 and overall non-relapse mortality rate was 12.5% and 25%, respectively. Allogeneic HSCT appears feasible in patients with transformed FL and is associated with acceptable treatment-related mortality and low relapse rates... - Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive diseaseJennifer A Woyach
The Ohio State University, Columbus, USA
Br J Haematol 148:754-9. 2010..2;p11.2) is a novel recurrent cytogenetic abnormality in CLL associated with early age at diagnosis and accelerated disease progression. Future efforts to identify genes disrupted by this translocation are warranted and ongoing... - The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivoDavid M Lucas
Department of Internal Medicine, The Ohio State University, Columbus, Ohio, USA
PLoS ONE 5:e10941. 2010..We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in B-cell malignancies... - Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathwayRosa Lapalombella
Division of Hematology and Oncology, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, USA
Blood 115:2619-29. 2010..This study is registered at http://clinicaltrials.gov as NCT00466895... - Effects of pretransplantation treatment with rituximab on outcomes of autologous stem-cell transplantation for non-Hodgkin's lymphomaAmy L Hoerr
School of Medicine, Siteman Cancer Center, Washington University, St. Louis, MO, USA
J Clin Oncol 22:4561-6. 2004.... - Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effectMehdi Hamadani
Biol Blood Marrow Transplant 14:480-3. 2008 - Antibodies for the treatment of diffuse large cell lymphomaKristie A Blum
Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO, USA
Semin Oncol 30:448-56. 2003..These agents may be most promising when combined with either chemotherapy or with rituximab. This review will summarize the use of rituximab in the therapy of diffuse large B-cell lymphoma and briefly describe antibodies in development... - Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignanciesPaula M Fracasso
Alvin J Siteman Cancer Center, St Louis, Missouri, USA
Cancer 95:2223-9. 2002..We conducted a Phase I trial to evaluate the maximum tolerated dose (MTD) and toxicities of this combination in patients with advanced malignancies...
Research Grants
- Targeting Transcriptional Repression in CLLKristie Blum; Fiscal Year: 2007..abstract_text> ..